MVP signs exclusive Penthrox deal for China
8 October 2018
MVP signs exclusive Penthrox deal for China with Daiichi Sankyo
Medical Developments International Limited (ASX: MVP) is delighted to announce it has entered into an exclusive Distribution and License Agreement with Daiichi Sankyo Company Limited (Daiichi Sankyo) for Penthrox? in China, Thailand and Vietnam. Daiichi Sankyo is listed on the Tokyo Stock Exchange (TSE: 4568)
Under the terms of the Agreement, Daiichi Sankyo will pay MVP up to $32.5 million US dollars (USD) (AUD $45.8m), including US$15 million upfront (AUD $21.1m), and sales-based milestone payments.
For further details please refer to the following link – ASX Announcement – (Penthrox – China)